Project description
Phase 2 development of drug against SARS-COV-1 and SARS-CoV-2
ExeVir in Belgium is developing a drug (XVR011) that shows best-in-class potential in neutralising SARS-COV-1 and SARS-CoV-2 and diminishing lung damage in hamsters. The single-domain antibodies developed in llama are smaller than in humans, reaching parts of the virus largely inaccessible to the human immune system. XVR011 inactivates spike proteins, binding highly conserved epitopes and preventing the virus from entering cells. The developer optimised antibodies for stability and safety and received regulatory approval for the pilot human clinical trial (Phase 1b). The objectives of the EU-financed XVR011 Phase 2 project are to demonstrate drug safety and efficacy in a global phase 2 clinical trial and to proceed with the set-up of the regulatory pathway toward the manufacturing process.
Fields of science
- engineering and technologymechanical engineeringmanufacturing engineering
- social scienceseconomics and businessbusiness and managemententrepreneurship
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesbasic medicineimmunology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
Programme(s)
Funding Scheme
HORIZON-AG - HORIZON Action Grant Budget-Based
Coordinator
9052 Gent
Belgium
See on map
Participants (3)
9052 Zwijnaarde - Gent
See on map
67120 Molsheim
See on map